v3.26.3
Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (2,895,632) $ (15,379,641)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation expense 174,836 215,069
Stock-based compensation 2,861,476 836,390
Amortization of right-of-use operating lease asset 685,570 594,829
Inducement expense 863,550
Write off of deferred offering costs 500,000
Amortization of debt discount 1,561,523
Foreign currency transaction (loss) gain included in other income (expenses) 1,918 (248)
Loss on initial and revaluation of derivative liabilities 3,395,884
Gain on revaluation of preferred stock liabilities (10,335,126)
Gain on debt extinguishment (3,801,413)
Gain on revaluation of earnout liability (19,500)
Change in assets and liabilities:    
Prepaid expenses and other current assets 627,578 (257,078)
Accounts payable 523,194 1,426,446
Accrued liabilities 152,343 (428,658)
Insurance payable (332,260)
Operating lease liability (723,381) (644,476)
Net cash used in operating activities (8,122,990) (12,273,817)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Proceeds from sale of equity securities 500,000
Net cash provided by investing activities 500,000
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercise of Series A Preferred warrants 500,000
Proceeds from convertible notes payable, net 4,485,200
Proceeds from notes payable 1,925,600
Proceeds from share purchases under ELOC, net of issuance costs 700,491 3,704,123
Proceeds received from sale of Series D Preferred Stock, net of issuance costs 2,560,981
Proceeds received from sale of common stock and warrants 588,000
Proceeds received from sale of pre-funded warrants, net of issuance costs 3,685,027
Payment of deferred offering costs (174,505)
Proceeds from exercise of pre-funded warrants 203
Cash redemption of Series C Preferred Stock (395,000)
Net cash provided by financing activities 7,111,291 10,468,829
Net decrease in cash, restricted cash and cash equivalents (1,011,699) (1,304,988)
Cash, restricted cash and cash equivalents at beginning of period 1,662,380 3,327,060
Cash, restricted cash and cash equivalents at end of period 650,681 2,022,072
The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the same such amounts shown in the consolidated statements of cash flows:    
Cash and cash equivalents 455,925 1,947,316
Restricted cash (short-term) 74,756 74,756
Restricted cash (long-term) 120,000
Cash, restricted cash and cash equivalents per consolidated statements of cash flows 650,681 2,022,072
Cash paid for:    
Interest 15,272
Income taxes
NON-CASH FINANCING ACTIVITIES:    
Conversion of Series A, Series B, Series C, Series D and Series E preferred stock to common stock 189,797 2,271,098
Increase in debt discount and derivative liabilities 4,485,200
Reclassification of convertible notes payable and accrued interest to notes payable 5,666,109
Reclassification of accounts payable to notes payable 500,000
Increase in operating lease right-of-use asset and operating lease liability 687,052
Reclassification of deferred offering costs to additional paid-in capital 112,232
Reclassification of accrued expenses to accounts payable 1,143,826
Issuance of Series D Preferred Stock for investment in equity securities 500,000
Write off of subscription receivable deemed offering costs 78,750
Reclassification of Series D and Series E preferred stock fair value to preferred stock liabilities 21,584,122
Reclassification of Series D preferred stock fair value from preferred stock liabilities to equity 7,322,990
Reclassification of Series E preferred stock fair value from preferred stock liabilities to paid-in capital upon conversion $ 196,406